Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02647918 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02647918 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT02647918, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of mild, moderate, or severe renal impairment, or end-stage renal disease (ESRD) requiring hemodialysis (HD), on the safety and tolerability of 1 or 2 single doses of sotagliflozin compared with healthy, demographically-matched subjects with normal renal function.
Interventions
- DRUG Sotagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02647918
The ClinicalTrials.gov registry entry for NCT02647918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sotagliflozin is the first listed.
NCT02647918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02647918 about?
NCT02647918 is a clinical study titled "Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function". The purpose of this study is to evaluate the effect of mild, moderate, or severe renal impairment, or end-stage renal disease (ESRD) requiring hemodialysis (HD), on the safety and tolerability of 1 or 2 single doses of sotagliflozin compared with healthy, demographically-matched subjects with normal...
What is the current status of trial NCT02647918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2015-12. Estimated completion is 2017-09.
What interventions are being tested in trial NCT02647918?
The interventions under investigation include: Sotagliflozin (DRUG).
Who is sponsoring clinical trial NCT02647918?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.